The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.

摘要: P25 is a major surface protein of Plasmodium ookinetes. Antibodies against prevent the formation oocysts in mosquito and thereby block transmission parasite through an endemic population. vivax transmission-blocking vaccines based on Pv25 have undergone human trials inhibit significantly. The current assay to determine activity (TBA) these sera, 'standard membrane feeding assay', complex can be performed by few groups worldwide that require both breeding facilities access volunteers naturally infected with P.vivax--a costly, uncontrolled source parasites. Here we report development novel assays TBA using two clones (Pv25DR Pv25DR3) transgenic rodent parasites (Plasmodium berghei) expressing Pv25. We show oocyst inhibited monoclonal antibody same kinetics exhibited wild type when exposed mouse antibodies targeted paralogous P28. Human sera from clinical vaccine trial Pv25DR Pv25DR3, whereas non-blocking did not. further determined simple ookinete vitro, obviate need for colonies. These results demonstrate malarias proteins species cheap, safe, tools testing sera. To this end cloned lines been deposited with, are freely available from, MR4.